Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.

Nat Commun · 2026 · PMC13187202 · PMID 41876542

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

Notably, PG-102 showed the lowest CD45+ area among groups, suggesting a possible trend toward reduced local inflammation compared to semaglutide or tirzepatide (Supplementary Fig. 3 ).

also in 939 other papers

showed a trendno p-value reported

PG-102 also reduced α-cell area compared with vehicle and showed a trend toward lower levels than semaglutide or tirzepatide, suggesting decreased glucagon production (Fig. 3e, i ).

also in 33,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.